Fulgent Genetics Q2 Losses Deepen as Billing Woes Crush Margins; Cash Burn Accelerates
FLGT is trading near its 52-week low of $13.46 (2.5% above the low).
Summary
Fulgent Genetics' Q2 2026 results reveal deepening operational problems: gross margin fell to 30%, operating loss nearly doubled, and cash reserves dropped $154M in six months. Billing system issues are crushing profitability, while government probes over past COVID-19 testing reimbursements remain a major overhang.
Key Events · Earnings and Guidance · FLGT
-
Gross Margin Collapse
Gross margin fell to 30% in Q2 2026 from 42% a year ago, driven by lower collection rates and higher fixed costs from the ongoing billing system transition. Management expects improvement as customizations are completed but cannot predict timing.
-
Operating Losses Widen
Operating loss increased 83% YoY to $36.1 million in Q2 2026, with net loss attributable to Fulgent reaching $29.5 million ($1.05 per share) versus $19.0 million a year ago.
-
Cash Burn Accelerates
Cash, cash equivalents, and marketable securities fell to $551.5 million from $705.5 million at year-end 2025. The company used $63.9 million for share repurchases and $55.6 million for the Bako acquisition, while operations consumed $16.7 million.
-
Goodwill Impairment Risk
An interim goodwill impairment test was triggered by the loss of a significant ANP customer and a sustained disconnect between market cap and tangible net asset value. The laboratory services reporting unit has only 11% headroom above carrying value, putting it at heightened risk of future impairment.
Analysis · FLGT · Industrial Applications And Services
Fulgent Genetics reported a sharp deterioration in its core laboratory business. Gross margin collapsed to 30% from 42% a year ago, driven by persistent billing system transition issues that are delaying collections and raising fixed costs. The operating loss nearly doubled to $36.1 million, and cash reserves fell by $154 million in six months, partly due to aggressive share buybacks. While the therapeutic development segment shows promise with upcoming FDA discussions for FID-007, the near-term story is dominated by operational struggles, shrinking cash runway, and unresolved government investigations that could result in material clawbacks of past COVID-19 reimbursements.
At the time of this filing, FLGT was trading at $13.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $574M. The 52-week trading range was $13.46 to $31.04. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.